Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe
International Journal of Environmental Research and Public Health · 2025
DOI: 10.3390/ijerph22040509 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Environmental Research and Public Health, 2025. Verfasst von Blessing Dzingirai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Mass Screening, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HTAi Scholarship Program.
Abstract (Originalsprache)
Background
The aim of this study was to assess the cost effectiveness of a screening and treatment intervention approach for chronic HCV infection in Zimbabwe.
Methods
Using a decision tree and a validated Markov model, we estimated the lifetime costs and health effects of screening for and treating HCV infections from a healthcare perspective. We evaluated three screening strategies, namely the following: i. no screening; ii. screening among the general population; and iii. screening among high-risk groups. Incremental cost effectiveness ratios were calculated for the strategies that were not dominated. We used deterministic and probabilistic sensitivity analyses to explore the impacts of parameter uncertainty on cost effectiveness outcomes.
Results
The strategy of screening among high-risk groups and treating with sofosbuvir/velpatasvir had an incremental cost of USD 1201 and incremental quality-adjusted life years (QALY) of 2.01, yielding an incremental cost effectiveness ratio (ICER) of USD 604 per QALY gained as compared to no screening. The ICER was below the 0.5 times the gross domestic product per capita parameter (USD 796), making the intervention potentially cost effective. The strategy to screen among the general population was dominated, because it costed more and resulted in fewer QALYs than its comparators.
Conclusions
Screening for HCV among high-risk populations followed by treatment using sofosbuvir/velpatasvir is cost effective under the assumptions made in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
- Department of Pharmacy and Pharmaceutical Sciences, University of Zimbabwe, Harare P.O. Box MP 167, Zimbabwe.
- Department of Medicine, College of Health Sciences, University of Zimbabwe, Harare P.O. Box MP 167, Zimbabwe.
- Department of Clinical Pharmacy and Toxicology, Martini Hospital, 9728 NL Groningen, The Netherlands.
- Sheffield Centre for Health and Related Research, School of Medicine and Population Health, University of Sheffield, Sheffield S10 2TN, UK.
ORCID-Profile: Blessing Dzingirai, Marinus van Hulst, Nyashadzaishe Mafirakureva
Förderung
- HTAi Scholarship Program
Zitieren
APA
Dzingirai, B., Katsidzira, L., Postma, M. J., Hulst, M. V., & Mafirakureva, N. (2025). Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph22040509
Vancouver
Dzingirai B, Katsidzira L, Postma MJ, Hulst MV, Mafirakureva N. Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe. International Journal of Environmental Research and Public Health. 2025. doi:10.3390/ijerph22040509
BibTeX
@article{Dzingirai2025,
author = {Dzingirai, Blessing and Katsidzira, Leolin and Postma, Maarten J and Hulst, Marinus van and Mafirakureva, Nyashadzaishe},
title = {Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe},
journal = {International Journal of Environmental Research and Public Health},
year = {2025},
doi = {10.3390/ijerph22040509}
}
EUVIMED